EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudiePragmatische StudieOpen Access · CC BY 4.0

A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis

Nina Wilson iD, Miranda Morton iD, Tara Homer iD, Ann Breeze Konkoth iD, Richard Joyce iD, Anneka Kershaw iD, Hazel Wilde iD, Alison Liddle iD, James Wason iD, Laura Ternent iD, Maria Allen iD, Robert Lord iD und 7 weitere

Health Technology Assessment · 2026

DOI: 10.3310/ggcc1111 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Health Technology Assessment, 2026. Verfasst von Nina Wilson und 18 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics Research Group, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Bronchiectasis, Bronchodilator Agents, Muscarinic Antagonists. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bronchiectasis is a long-term lung condition associated with bronchial dilatation, chronic inflammation and infection. Treatment is often empirical or extrapolated from other lung conditions, for example the use of inhaled therapies licensed for use in asthma or chronic obstructive pulmonary disease. Inhaled therapies, such as corticosteroids or long-acting bronchodilators (long-acting beta agonists or long-acting muscarinic antagonists), are commonly used in bronchiectasis despite scanty evidence on exacerbation reduction.

Objective

To assess whether: dual bronchodilators (long-acting beta agonists/long-acting muscarinic antagonists) either as stand-alone therapy or in combination with inhaled corticosteroid are superior to placebo at reducing mean exacerbation rates over 12 months dual bronchodilators (long-acting beta agonists/long-acting muscarinic antagonists) are non-inferior to triple therapy (inhaled corticosteroid/long-acting beta agonists/long-acting muscarinic antagonists) at reducing mean exacerbation rates over 12 months.

Design

Pragmatic, multicentre, placebo-controlled, three-arm, double-blinded, prospective, randomised controlled trial incorporating a 12-month internal pilot. Target population Six hundred adults with bronchiectasis and history of ≥ 2 exacerbations in any 12-month period within the preceding 2 years.

Setting

United Kingdom National Health Service secondary care sites.

Interventions

Twelve months, one puff daily of either dual therapy [55 μg umeclidinium (long-acting muscarinic antagonists) and 22 μg vilanterol (long-acting beta agonists)], triple therapy [dual therapy plus 92 μg fluticasone furoate (inhaled corticosteroid)] or matched placebo dry powder inhalers, randomised in a 2 : 2 : 1 ratio, respectively. Outcome measures Primary: number of participants reported bronchiectasis exacerbations requiring treatment with antibiotics during the 12-month treatment period. Primary economic: incremental cost per quality-adjusted life-year gained at 12 months.

Results

Recruitment rates did not follow projections due to the COVID-19 pandemic; 85 potentially eligible patients were screened, of whom 33 (39%) were randomised. Of the randomised participants, 30 (91%) completed follow-up at 12 months; 3 participants withdrew [1/14 (7%) dual therapy, 1/12 (8%) triple therapy and 1/7 (14%) placebo]. Five participants discontinued therapy during the trial [1/14 (7%) dual therapy, 2/12 (17%) triple therapy and 2/7 (29%) placebo]. Given the small sample size, the statistical and economic analyses are descriptive and exploratory. Exacerbation data were available for 32/33 (97%) of randomised participants (13 dual therapy, 12 triple therapy and 7 placebo). The median number of exacerbations during the follow-up (the primary outcome) was 1 (interquartile range 0–3) for dual therapy, 2 (1, 2.5) for triple therapy and 3 (2, 3) for placebo. No safety concerns were identified. Complete resource-use and quality-of-life data were available for 30/33 (91%) participants.

Conclusions

COVID-19 impacted delivery of the trial, affecting staff capacity, setting up of timelines, and ultimately, recruitment to the pilot. There was good retention and data completeness within the trial randomised participants. The trial is unable to provide evidence on the superiority or cost-effectiveness of dual or triple therapy to placebo at reducing mean exacerbation rates over 12 months or the non-inferiority of dual to triple therapy. Future work and limitations The main limitation of this work is the small sample size that prevents any firm conclusions to be made. However, the results do suggest that there is a signal of efficacy and that a larger trial is needed to provide valuable clinical evidence. These results underscore the importance of completing a large-scale trial of these therapies to help improve the understanding and best treatment for patients with bronchiectasis. Funding This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR127460.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BronchiectasisBronchodilator AgentsMuscarinic AntagonistsHumansDouble-Blind MethodFemaleAdministration, InhalationDrug Therapy, CombinationMaleMiddle AgedAgedPilot ProjectsAdrenal Cortex HormonesQuinuclidinesChlorobenzenesUnited Kingdom

Stichwörter der Autor:innen

ADULTBRONCHIECTASISBRONCHODILATOR AGENTSFLUTICASONE FUROATEHUMANSINHALED CORTICOSTEROIDMUSCARINIC ANTAGONISTSPROSPECTIVE STUDIES

Substanzen

Bronchodilator AgentsMuscarinic AntagonistsAdrenal Cortex HormonesQuinuclidinesChlorobenzenesGSK573719

Autor:innen und Institutionen

  • Biostatistics Research Group, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Newcastle Clinical Trials Unit, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Health Economics Group, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Wythenshawe Hospital Manchester University NHS Foundation Trust, Manchester, UK.
  • North Tyneside General Hospital, Northumbria Healthcare NHS Foundation Trust, North Tyneside, UK.

ORCID-Profile: Nina Wilson, Miranda Morton, Tara Homer, Ann Breeze Konkoth, Richard Joyce, Anneka Kershaw, Hazel Wilde, Alison Liddle, James Wason, Laura Ternent, Maria Allen, Robert Lord, John Steer, Graham Devereux, James D Chalmers, Adam T Hill, Charles S Haworth, John R Hurst, And Anthony De Soyza

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Wilson, N., Morton, M., Homer, T., Breeze Konkoth, A., Joyce, R., Kershaw, A., Wilde, H., Liddle, A., Wason, J., Ternent, L., Allen, M., Lord, R., Steer, J., Devereux, G., Chalmers, J. D., Hill, A. T., Haworth, C. S., Hurst, J. R., & De Soyza, A. A. (2026). A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis. Health Technology Assessment. https://doi.org/10.3310/ggcc1111

Vancouver

Wilson N, Morton M, Homer T, Breeze Konkoth A, Joyce R, Kershaw A, et al. A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis. Health Technology Assessment. 2026. doi:10.3310/ggcc1111

BibTeX
@article{Wilson2026,
  author = {Wilson, Nina and Morton, Miranda and Homer, Tara and Breeze Konkoth, Ann and Joyce, Richard and Kershaw, Anneka and Wilde, Hazel and Liddle, Alison and Wason, James and Ternent, Laura and Allen, Maria and Lord, Robert and Steer, John and Devereux, Graham and Chalmers, James D and Hill, Adam T and Haworth, Charles S and Hurst, John R and De Soyza, And Anthony},
  title = {A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis},
  journal = {Health Technology Assessment},
  year = {2026},
  doi = {10.3310/ggcc1111}
}
Kostenlos starten →